Novalar licenses local anaesthesia reversal agent to Sanofi-Aventis
This article was originally published in Scrip
Executive Summary
US-based Novalar has granted an exclusive licence to Sanofi-Aventis Deutschland for its local dental anaesthesia reversal agent OraVerse (phentolamine mesylate).